The frequency of POLE-mutation in endometrial carcinoma and prognostic implications: a systemic review and meta-analysis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: Endometrial carcinoma (EC) is classified into four distinct molecular subgroups including ultramutated DNA polymerase epsilon (POLE). POLE-mutated tumors have the best prognosis and are a promising target for immunotherapy. This meta-analysis consolidated the reported variation of POLE-mutant frequency and assessed prognostic value in EC. Methods: Internet searches explored scientific data bases: EMBASE, PubMed, and the Cochrane Central Register of Controlled Trials databases. Data was extracted from eligible studies including: sample size, number of positive POLE-mutant cases, sequencing information, clinicopathologic data, and survival data. Meta-analysis and a random-effects model produced pooled estimates of POLE frequency and prognostic parameters using 95% confidence intervals (CI), hazard ratios (HR), and odd ratios (OR). Results: Six thousand three hundred and forty-six EC patient cases were pooled from 25 studies. The pooled proportion of POLE gene mutation in EC was 8.59% (95% CI, 7.01 to 10.32), of which 8.22% (95% CI, 6.27 to 10.42) were type I and 0.93% (95% CI, 0.34 to 1.81) type 2. Clinicopathologic data showed that POLE-mutated tumors are mostly endometrioid. They present at higher levels in earlier stages (I–II) of EC (89.51%; 95% CI, 81.11 to 95.66) at the highest grade III (51.53%; 95% CI, 36.08 to 66.84) with reduced myometrial invasion (OR, 1.48, 95% CI, 0.99 to 2.20). Survival analysis indicated favorable overall survival (HR, 0.90), disease-specific survival (HR, 0.41), and progression-free survival (HR, 0.23) for POLE mutant EC. Conclusions: Almost one-tenth of EC patients have POLE-mutated tumors. Given their improved prognostic potential, identifying the POLE mutation status is key for the management of EC patients.
Abstract
Background: Endometrial carcinoma (EC) is classified into four distinct molecular subgroups including ultramutated DNA polymerase epsilon (POLE). POLE-mutated tumors have the best prognosis and are a promising target for immunotherapy. This meta-analysis consolidated the reported variation of POLE-mutant frequency and assessed prognostic value in EC. Methods: Internet searches explored scientific data bases: EMBASE, PubMed, and the Cochrane Central Register of Controlled Trials databases. Data was extracted from eligible studies including: sample size, number of positive POLE-mutant cases, sequencing information, clinicopathologic data, and survival data. Meta-analysis and a random-effects model produced pooled estimates of POLE frequency and prognostic parameters using 95% confidence intervals (CI), hazard ratios (HR), and odd ratios (OR). Results: Six thousand three hundred and forty-six EC patient cases were pooled from 25 studies. The pooled proportion of POLE gene mutation in EC was 8.59% (95% CI, 7.01 to 10.32), of which 8.22% (95% CI, 6.27 to 10.42) were type I and 0.93% (95% CI, 0.34 to 1.81) type 2. Clinicopathologic data showed that POLE-mutated tumors are mostly endometrioid. They present at higher levels in earlier stages (I–II) of EC (89.51%; 95% CI, 81.11 to 95.66) at the highest grade III (51.53%; 95% CI, 36.08 to 66.84) with reduced myometrial invasion (OR, 1.48, 95% CI, 0.99 to 2.20). Survival analysis indicated favorable overall survival (HR, 0.90), disease-specific survival (HR, 0.41), and progression-free survival (HR, 0.23) for POLE mutant EC. Conclusions: Almost one-tenth of EC patients have POLE-mutated tumors. Given their improved prognostic potential, identifying the POLE mutation status is key for the management of EC patients.
참고문헌 (37)
- Bell DW, "Molecular genetics of endometrial carcinoma", Annu Rev Pathol, 14, pp.339~367 (2019)
- Howlader N, "SEER cancer statistics review, 1975-2011" (2014), National Cancer Institute
- Siegel RL, "Cancer statistics, 2015", CA Cancer J Clin, 65, pp.5~29 (2015)
- Spurdle AB, "Endometrial cancer gene panels : clinical diagnostic vs research germline DNA testing", Mod Pathol, 30, pp.1048~1068 (2017)
- Stelloo E, "High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma", Gynecol Oncol, 133, pp.197~204 (2014)
- Hussein YR, "Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations", Mod Pathol, 28, pp.505~514 (2015)
- Church DN, "Prognostic significance of POLE proofreading mutations in endometrial cancer", J Natl Cancer Inst, 107, pp.402~ (2015)
- Cancer Genome Atlas Research Network, "Integrated genomic characterization of endometrial carcinoma", Nature, 497, pp.67~73 (2013)
- Auguste A, "Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers : a TransPORTEC initiative", Mod Pathol, 31, pp.1851~1861 (2018)
- Talhouk A, "A clinically applicable molecular-based classification for endometrial cancers", Br J Cancer, 113, pp.299~310 (2015)
- Stelloo E, "Refining prognosis and identifying targetable pathways for high-risk endometrial cancer : a Trans-PORTEC initiative", Mod Pathol, 28, pp.836~844 (2015)
- Eggink FA, "Immunological profiling of molecularly classified high-risk endometrial cancers identifies POLE-mutant and microsatellite unstable carcinomas as candidates for checkpoint inhibition", Oncoimmunology, 6, pp.e1264565~ (2017)
- Bosse T, "Molecular classification of grade 3 endometrioid endometrial cancers identifies distinct prognostic subgroups", Am J Surg Pathol, 42, pp.561~568 (2018)
- Billingsley CC, "Polymerase varepsilon(POLE)mutations in endometrial cancer : clinical outcomes and implications for Lynch syndrome testing", Cancer, 121, pp.386~394 (2015)
- Le Gallo M, "Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing", Cancer, 123, pp.3261~3268 (2017)
- Talhouk A, "Confirmation of ProMisE : a simple, genomics-based clinical classifier for endometrial cancer", Cancer, 123, pp.802~813 (2017)
- Rosa-Rosa JM, "Molecular genetic heterogeneity in undifferentiated endometrial carcinomas", Mod Pathol, 29, pp.1390~1398 (2016)
- Hoang LN, "Targeted mutation analysis of endometrial clear cell carcinoma", Histopathology, 66, pp.664~674 (2015)
- Abdulfatah E, "Molecular classification of endometrial carcinoma applied to endometrial biopsy specimens : towards early personalized patient management", Gynecol Oncol, 154, pp.467~474 (2019)
- Stelloo E, "Improved risk assessment by integrating molecular and clinicopathological factors in early-stage endometrial cancer-combined analysis of the PORTEC cohorts", Clin Cancer Res, 22, pp.4215~4224 (2016)
- Imboden S, "Phenotype of POLE-mutated endometrial cancer", PLoS One, 14, pp.e0214318~ (2019)
- Billingsley CC, "Prognostic significance of POLE exonuclease domain mutations in high-grade endometrioid endometrial cancer on survival and recurrence : a subanalysis", Int J Gynecol Cancer, 26, pp.933~938 (2016)
- Talhouk A, "Molecular classification of endometrial carcinoma on diagnostic specimens is highly concordant with final hysterectomy : earlier prognostic information to guide treatment", Gynecol Oncol, 143, pp.46~53 (2016)
- Wong A, "Mutation spectrum of POLE and POLD1 mutations in South East Asian women presenting with grade 3 endometrioid endometrial carcinomas", Gynecol Oncol, 141, pp.113~120 (2016)
- Wortman BG, "Ten-year results of the PORTEC-2 trial for high-intermediate risk endometrial carcinoma : improving patient selection for adjuvant therapy", Br J Cancer, 119, pp.1067~1074 (2018)
- Kommoss FK, "L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile", Br J Cancer, 119, pp.480~486 (2018)
- Karnezis AN, "Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification", J Pathol Clin Res, 3, pp.279~293 (2017)
- Espinosa I, "Undifferentiated and dedifferentiated endometrial carcinomas with POLE exonuclease domain mutations have a favorable prognosis", Am J Surg Pathol, 41, pp.1121~1128 (2017)
- DeLair DF, "The genetic landscape of endometrial clear cell carcinomas", J Pathol, 243, pp.230~241 (2017)
- Meng B, "POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium", Gynecol Oncol, 134, pp.15~19 (2014)
- Bellone S, "Polymerase epsilon(POLE)ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro", Gynecol Oncol, 144, pp.146~152 (2017)
- Moher D, "Preferred reporting items for systematic review and meta-analysis protocols(PRISMA-P)2015statement", Syst Rev, 4, pp.1~ (2015)
- "MedCalc statistical software version 13.0.6" (2014)[URL]
- Jumaah AS, "Increased PTEN gene expression in patients with endometrial carcinoma from areas of high risk depleted uranium exposure", BMC Res Notes, 12, pp.708~ (2019)
- van Gool IC, "POLE proofreading mutations elicit an antitumor immune response in endometrial cancer", Clin Cancer Res, 21, pp.3347~3355 (2015)
- Bakhsh S, "Histopathological features of endometrial carcinomas associated with POLE mutations : implications for decisions about adjuvant therapy", Histopathology, 68, pp.916~924 (2016)
- Sterne JA, "Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials", BMJ, 343, pp.d4002~ (2011)